News
CELC
67.05
-4.72%
-3.32
Celcuity announces FDA acceptance of sNDA for Revtorpyk
TipRanks · 1d ago
Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive
Benzinga · 1d ago
Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 1d ago
Is Celcuity (CELC) Undervalued After Its Q3 Loss Raised Fresh Questions?
Simply Wall St · 1d ago
Celcuity Price Target Cut to $150.00/Share From $155.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Celcuity Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
Benzinga · 1d ago
Weekly Report: what happened at CELC last week (1102-1106)?
Weekly Report · 1d ago
How Investors Are Reacting To Celcuity (CELC) Wider Loss And Trial Data
Simply Wall St · 4d ago
Celcuity (CELC) Q3 2026 Earnings Call Transcript
The Motley Fool · 4d ago
Celcuity Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Celcuity Price Target Cut to $169.00/Share From $171.00 by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169
Benzinga · 4d ago
Cantor Fitzgerald Sticks to Their Buy Rating for Celcuity (CELC)
TipRanks · 4d ago
Celcuity price target lowered to $135 from $150 at Stifel
TipRanks · 4d ago
Celcuity price target lowered to $169 from $171 at Guggenheim
TipRanks · 4d ago
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Commercial Launch of REVTORPYK
NASDAQ · 4d ago
Celcuity Non-GAAP EPS of -$1.21 beats by $0.32
Seeking Alpha · 5d ago
Press Release: Celcuity Inc. Reports Third -2-
Dow Jones · 5d ago
Press Release: Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 5d ago
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.